Literature DB >> 15336332

Medicare cost in matched hospice and non-hospice cohorts.

Bruce Pyenson1, Stephen Connor, Kathryn Fitch, Barry Kinzbrunner.   

Abstract

Hospice care is perceived as enhancing life quality for patients with advanced, incurable illness, but cost comparisons to non-hospice patients are difficult to make. The very large Medicare expenditures for care given during the end of life, combined with the pressure on Medicare spending, make this information important. We sought to identify cost differences between patients who do and do not elect to receive Medicare-paid hospice benefits. We introduce an innovative prospective/retrospective case-control method that we used to study 8,700 patients from a sample of 5% of the entire Medicare beneficiary population for 1999-2000 associated with 16 narrowly defined indicative markers. For the majority of cohorts, mean and median Medicare costs were lower for patients enrolled in hospice care. The lower costs were not associated with shorter duration until death. For important terminal medical conditions, including non-cancers, costs are lower for patients receiving hospice care. The lower cost is not associated with shorter time until death, and appears to be associated with longer mean time until death.

Entities:  

Mesh:

Year:  2004        PMID: 15336332     DOI: 10.1016/j.jpainsymman.2004.05.003

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  42 in total

1.  Increased access to palliative care and hospice services: opportunities to improve value in health care.

Authors:  Diane E Meier
Journal:  Milbank Q       Date:  2011-09       Impact factor: 4.911

2.  Hospice care and resource utilization in Medicare beneficiaries with heart failure.

Authors:  Saul Blecker; Gerard F Anderson; Robert Herbert; Nae-Yuh Wang; Frederick L Brancati
Journal:  Med Care       Date:  2011-11       Impact factor: 2.983

3.  End-of-life care in Medicare beneficiaries dying with pancreatic cancer.

Authors:  Kristin M Sheffield; Casey A Boyd; Jamie Benarroch-Gampel; Yong-Fang Kuo; Catherine D Cooksley; Taylor S Riall
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

4.  End-of-life care at a community cancer center.

Authors:  David E Cowall; Bennett W Yu; Sandra L Heineken; Elizabeth N Lewis; Vishal Chaudhry; Joan M Daugherty
Journal:  J Oncol Pract       Date:  2012-05-22       Impact factor: 3.840

5.  Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay.

Authors:  Amy S Kelley; Partha Deb; Qingling Du; Melissa D Aldridge Carlson; R Sean Morrison
Journal:  Health Aff (Millwood)       Date:  2013-03       Impact factor: 6.301

6.  High Intensity of End-of-Life Care Among Adolescent and Young Adult Cancer Patients in the New York State Medicaid Program.

Authors:  Jennifer W Mack; Kun Chen; Francis P Boscoe; Foster C Gesten; Patrick J Roohan; Maria J Schymura; Deborah Schrag
Journal:  Med Care       Date:  2015-12       Impact factor: 2.983

7.  Race and residence: intercounty variation in black-white differences in hospice use.

Authors:  Kimberly S Johnson; Maragatha Kuchibhatla; Richard Payne; James A Tulsky
Journal:  J Pain Symptom Manage       Date:  2013-03-21       Impact factor: 3.612

8.  Heart rate variability and length of survival in hospice cancer patients.

Authors:  Do Hoon Kim; Jeong A Kim; Youn Seon Choi; Su Hyun Kim; June Young Lee; Young Eun Kim
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

9.  Hospice shared-care saved medical expenditure and reduced the likelihood of intensive medical utilization among advanced cancer patients in Taiwan--a nationwide survey.

Authors:  Wen-Yuan Lin; Tai-Yuan Chiu; Chih-Te Ho; Lance E Davidson; Hua-Shui Hsu; Chiu-Shong Liu; Chang-Fang Chiu; Ching-Tien Peng; Chih-Yi Chen; Wen-Yu Hu; Ling-Nu Hsu; Chia-Ing Li; Tsai-Chung Li; Chin-Yu Lin; Ching-Yu Chen; Cheng-Chieh Lin
Journal:  Support Care Cancer       Date:  2014-02-26       Impact factor: 3.603

10.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.